-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, September 24, 2021/PRNewswire/ - 2021 Zhongguancun Forum will be held from September 24 to 28
.
Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) will bring the company's self-developed second-generation pan-TRK small molecule inhibitor ICP-723 for the first time at Zhongguancun Forum 2021, and will participate in international technology transactions at the forum Conference "New Technology and New Products First Launch and Promotion Conference"
ICP-723 is a Class 1 innovative drug with independent intellectual property rights owned by Nuocheng Jianhua worldwide.
It is used to treat advanced or metastatic solid tumors carrying NTRK fusion genes, including lung cancer, breast cancer, colorectal cancer, thyroid cancer, etc.
, and Patients who are resistant to the first generation of TRK inhibitors
.
Pre-clinical studies have shown that ICP-723 has high activity and good safety against a variety of solid tumors, and has the potential to provide a broad-spectrum anti-cancer therapy for patients with solid tumors with NTRK gene fusion
.
Currently, ICP-723 is conducting clinical trials in China and the United States, mainly to evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumors, and to evaluate the resistance of ICP-723 to NTRK fusion gene-positive cancers.
In China, ICP-723 is undergoing a phase I dose escalation (1 mg, 2 mg, 3 mg, and 4 mg) study.
Two eligible NTRK fusion-positive patients showed efficacy after administration
.
In the first tumor assessment at the end of the first cycle (or on the 28th day), the tumors of the patients in the 3 mg group shrank by more than 20%; the patients in the 4 mg group achieved partial remission (PR) for the first time
In the 2021 Zhongguancun Forum Exhibition (Expo), Nuocheng Jianhua demonstrated the national "Major New Drug Creation" special achievement-the new Bruton's tyrosine kinase (BTK) inhibitor obritinib
.
Obrutinib is a Class 1 innovative drug independently developed by Nuocheng Jianhua and was approved for listing in China at the end of last year
.
Obatinib has a more precise target selectivity, with a nearly 100% occupancy rate of BTK targets; there is little difference between individuals and no obvious inhibitory effect on other kinases.
Dr.
Cui Jisong, co-founder, chairman and CEO of Nuocheng Jianhua, said: “This year, the Zhongguancun Forum will be fully upgraded and the Zhongguancun Forum will be turned into a national platform for global scientific and technological innovation exchanges and cooperation
.
We are very happy to participate in this grand event.
After 14 years of development, the Zhongguancun Forum has become a global, comprehensive and open high-end international forum for technological innovation
.
About Nuocheng Jianhua
Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma and solid tumors And autoimmune diseases
.
Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages
